Due to the role of IDH1/IDH2 mutations in the pathogenesis of leukemia, as well as the promising results of preclinical studies indicating the potential ability of mIDH1/mIDH2 inhibitors to restore the normal differentiation of hematopoietic cells, it was decided to evaluate the effectiveness of the use of mIDH1/mIDH2 inhibitors in AML therapy in clinical trials. Here, IDH2 is linked to acute myeloid leukemia.